

Remote ischemic preconditioning in patients with intermittent claudication

Glauco Fernandes Saes, Antonio Eduardo Zerati, Nelson Wolosker, Luciana Ragazzo, Ruben Miguel Ayzin Rosoky, Raphael Mendes Ritti-Dias, Gabriel Grizzo Cucato, Marcelo Chehuen, Breno Quintella Farah, Pedro Puech-Leão

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Disciplina de Cirurgia Vascular, Ambulatório de Claudicação, São Paulo/SP, Brasil.

OBJECTIVE: Remote ischemic preconditioning (RIPC) is a phenomenon in which a short period of sub-lethal ischemia in one organ protects against subsequent bouts of ischemia in another organ. We hypothesized that RIPC in patients with intermittent claudication would increase muscle tissue resistance to ischemia, thereby resulting in an increased ability to walk.

METHODS: In a claudication clinic, 52 ambulatory patients who presented with complaints of intermittent claudication in the lower limbs associated with an absent or reduced arterial pulse in the symptomatic limb and/or an ankle-brachial index <0.90 were recruited for this study. The patients were randomly divided into three groups (A, B and C). All of the patients underwent two tests on a treadmill according to the Gardener protocol. Group A was tested first without RIPC. Group A was subjected to RIPC prior to the second treadmill test. Group B was subjected to RIPC prior to the first treadmill test and then was subjected to a treadmill test without RIPC. In Group C (control group), both treadmill tests were performed without RIPC. The first and second tests were conducted seven days apart. Brazilian Clinical Trials: RBR-7TF6TM.

RESULTS: Group A showed a significant increase in the initial claudication distance in the second test compared to the first test.

CONCLUSION: RIPC increased the initial claudication distance in patients with intermittent claudication; however, RIPC did not affect the total walking distance of the patients.

KEYWORDS: Intermittent Claudication; Ischemic Preconditioning; Peripheral Arterial Disease.

Saes GF, Zerati AE, Wolosker N, Ragazzo L, Rosoky RM, Ritti-Dias RM, et al. Remote ischemic preconditioning in patients with intermittent claudication. *Clinics*. 2013;68(4):495-499.

Received for publication on October 25, 2012; First review completed on November 21, 2012; Accepted for publication on December 19, 2012

E-mail: glauco.saes@terra.com.br

Tel.: 55 11 98111-2860

■ INTRODUCTION

Ischemic preconditioning (IPC) was first described in 1986 by Murry et al. (1) as an increase in cellular resistance to myocardial ischemia when the heart is exposed to periods of brief non-lethal ischemia interspersed with reperfusion. In 1993, Pryzklenk et al. (2) demonstrated that an increase in cell resistance to ischemia also occurred in other tissues that were not directly subjected to ischemia. This phenomenon was named remote ischemic preconditioning (RIPC) (3-18). Although some authors question whether RIPC actually occurs (19), many studies have demonstrated the beneficial

effects on myocardial cells after transient ischemia is encountered by other tissue (20-22). Cells in organs other than the heart are sensitive to the protective effects that follow ischemia-reperfusion injury of the myocardial tissue or other distant tissues (23-26). Based on evidence of RIPC occurring in other tissues, we predicted that RIPC could occur in patients with intermittent claudication (IC), thereby making the muscles more resistant to ischemia and increasing the ability of these individuals to walk. To test this hypothesis, we performed gait tests in patients with claudication with and without prior RIPC and then compared the initial claudication distance (ICD) and the total walking distance (TWD).

■ METHODS

This study was performed at the Intermittent Claudication Clinic of the Hospital das Clínicas, Faculdade de Medicina at the Universidade de São Paulo after receiving approval from the local ethics committee. All of the participants signed informed consent forms prior to

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

DOI: 10.6061/clinics/2013(04)10



their enrollment. This study was registered as a clinical trial in the Brazilian Clinical Trials Registry (trial RBR-7TF6TM).

Between January 2009 and May 2011, 52 consecutive ambulatory patients complaining of typical intermittent claudication (IC) in one or both lower limbs that was associated with an absent or reduced arterial pulse in the symptomatic limb and/or an ankle-brachial index <0.90 were recruited for this study. Physical examinations of the upper limbs revealed normal physiology in all the study participants.

The patients were randomly divided into three groups (A, B and C) and underwent two treadmill tests according to the Gardener protocol. Group A was first tested on a treadmill without undergoing RIPC, and then Group A was tested on a treadmill after undergoing RIPC. Group B was first tested on a treadmill after receiving RIPC, and then Group B was tested on a treadmill without receiving RIPC. In Group C (control group), both treadmill tests were conducted without the patient receiving RIPC. The treadmill tests were conducted seven days apart.

The tests were conducted on a treadmill running at a fixed speed of 3.2 km/h, and the required effort was progressively increased (2% increase in the incline every 2 minutes). The initial claudication distance (ICD), which describes the maximum distance a patient can walk without experiencing leg pain, and the total walking distance (TWD), which refers to the distance walked before the patient could not continue walking, were recorded in each test.

RIPC was implemented according to a previously described protocol (22), which is detailed below.

Ninety minutes before exercising on the treadmill, an inflated cuff was positioned on the non-dominant upper limb of the participant three times for five minutes each time. Between each period of inflation, the cuff was deflated for five minutes.

The participants were advised to avoid consuming the following substances, which have been suggested to interfere with the process of ischemic preconditioning (RIPC), within two hours of the test: cilostazol, sildenafil, dipyridamole, glibenclamide, aminophylline, nicorandil, phenylephrine, angiotensin-converting enzyme inhibitors, angiotensin receptor blocker II, statins and steroids, caffeine and alcohol.

Considering the experimental nature of this study, the number of subjects included in each group was calculated based on sample power, as proposed by J. Eng (41).

Statistical analysis

The statistical analyses were conducted using the Statistic 5.1 software (StatSoft, Inc., Tulsa, OK, USA). The data were

first tested for normality and homogeneity of variance using the Shapiro-Wilk and Levene tests, respectively.

To compare the general characteristics of the three experimental groups, we used an analysis of variance (ANOVA) of one factor for continuous variables and the chi-squared or Fisher's exact test for categorical variables. To compare ICD and TWD between the three experimental groups, a two factorial ANOVA for repeated measurements was used considering the group (A, B and C) as an independent factor and the time (first or second test) as the repeated factor. When significant effects were observed, the post-hoc Duncan's test was used to verify differences.

Data are presented as relative frequencies, means and standard deviations. For all of the analyses, a significance level of $p < 0.05$ was assumed.

RESULTS

A total of 52 patients were analyzed in this study, which included 38 males and 14 females. General patient characteristics are shown in Table 1. No differences were observed between the groups regarding age, race, gender, diabetes prevalence, hypertension prevalence and smoking history. However, Group C had a higher prevalence of dyslipidemia relative to the other groups ($p = 0.017$).

Table 2 shows the effect of RIPC on the walking capacity of the IC patients. Group A and Group C patients had higher initial claudication distances (ICDs) in the second test relative to the first test. However, no differences were found in Group B. Furthermore, the ICD was greater in Group A patients when compared with the other groups. Table 2 also shows that the total walking distance (TWD) was lower in the first test than in the second test for Group A and Group B. However, there were no significant differences between the groups (see Figures 1 and 2).

DISCUSSION

Initial studies analyzing RIPC used animal models in an attempt to show the effects of RIPC by comparing the area of injury in tissues exposed and not exposed to periods of ischemia-reperfusion induced by ligating the arterial feeder vessel. Pryzklenk et al. were the first to demonstrate that small cycles of coronary artery occlusions in dogs protected the myocardial cells from longer periods of ischemia (2). Later, the protective effect induced by ischemia could be transferred to non-preconditioned rabbits that received whole blood transfusions from rabbits that were subjected to RIPC (29). Other studies have shown reductions in the area of myocardial infarction in animals subjected to RIPC induced by the intermittent occlusion of the femoral, renal

Table 1 - General characteristics of patients with intermittent claudication.

Variables	Group A (n = 18)	Group B (n = 16)	Group C (n = 18)	p-value
Age (years)	65.8 ± 7.9	60.5 ± 9.5	64.0 ± 9.9	0.145
Gender (% males)	72.2	69.8	77.8	0.835
Skin color (% whites)	72.2	75.0	77.8	0.929
Risk factors				
Diabetes mellitus (%)	23.5	37.5	44.4	0.422
Hypertension (%)	77.8	62.5	94.4	0.074
Dyslipidemia (%)	38.9	25.0	72.2	0.017
History of smoking	94.4	93.8	83.3	0.456

Values are expressed as the mean ± standard deviation.

**Table 2** - Effect of remote ischemic preconditioning (RIPC) on initial claudication distance (ICD) and total walking distance (TWD) in the three experimental groups.

	First test	Second test	Group effect	Moment effect	Interaction effect
ICD (m)					
Group A (n = 18)	164 ± 79	197 ± 85*	0.518	0.039	0.045
Group B (n = 16)	147 ± 112	134 ± 91 [†]			
Group C (n = 18)	143 ± 114	173 ± 135* [†]			
TWD (m)					
Group A (n = 18)	352 ± 173	435 ± 182*	0.692	<0.001	0.595
Group B (n = 16)	309 ± 168	364 ± 218*			
Group C (n = 18)	308 ± 214	421 ± 279*			

Values are expressed as the mean ± standard deviation. *Significant difference compared with the first test; [†]Different from Group A ($p < 0.05$).

Group effect indicates whether a statistically significant difference exists between the groups (A, B and C).

Moment effect indicates whether a statistically significant intra-patient difference exists between the results from the first and second treadmill tests (days 1 and 7).

The interaction effect indicates whether a statistically significant difference exists in both the group and moment effects.



and mesenteric arteries (30-32). In addition to the cardiac muscle, other organs and tissues have been shown to respond to the protective effect of RIPC, including the lungs, kidneys, liver and skeletal muscle (23,33-35).

Of the few RIPC studies that have been conducted in human subjects, some have shown that RIPC protects endothelial function after ischemia-reperfusion injury (22,36,37), and other studies have shown the protection of myocardial cells in patients undergoing cardiac operations (38,39). For patients undergoing segmental hepatectomy, RIPC before the operation led to reduced liver enzymes during the immediate postoperative period compared with patients in whom RIPC was not performed, but no differences in mortality and morbidity were observed (40). RIPC may be mediated by humoral factors and/or through the neurogenic pathway consisting of an early phase that begins after the completion of preconditioning and persists for upwards of 4 hours, and a late phase that begins approximately 24 hours after RIPC and persists for nearly 48 hours. Several humoral factors appear to be involved in mediating RIPC, including opioids, nitric oxide, adenosine, catecholamines, bradykinin, heat shock proteins, heme oxygenase, tumor necrosis factor- α , free radicals, prostaglandins and angiotensin. Organs subjected to ischemia have been shown to activate the protein kinase C

intracellular pathway resulting in the nuclear translocation of nuclear factor kappa beta and the subsequent activation of nitric oxide synthesis. Common mechanisms involved in target organs in the early and late stages of RIPC remain unclear; however, some studies have suggested roles for mitochondrial K_{ATP} channels and neutrophils.

RIPC is of particular interest with respect to peripheral arterial disease such as intermittent claudication (IC). RIPC could explain, at least partially, the success of physical training in treating patients with IC. The mechanism by which exercise improves the symptoms of vascular-mediated IC remains poorly understood. Furthermore, the initial concept that physical activity promotes increased collateral circulation by stimulating neangiogenesis lacks definitive evidence (27). Current theories have sought to associate the improvement in walking distance to changes in muscle metabolism induced by exercise (28). Repeated ischemia-reperfusion events caused by physical training could be the stimulus for intracellular biochemical changes leading to a more effective use of oxygen by the muscle and an improvement in endothelial function. This theory is based on the concept of RIPC.

In patients with claudication, a major goal of treatment is to improve the quality of life by increasing the ICD and TWD. Therefore, these parameters were used in our study

**Figure 1** - Effect of remote ischemic preconditioning (RIPC) on the initial claudication distance (ICD).**Figure 2** - Effect of remote ischemic preconditioning (RIPC) on the total walking distance (TWD).



to evaluate patient responses to RIPC treatment using each patient as his/her own control. We compared the distances walked in each treadmill test with and without RIPC. Because many patients were not used to walking on a treadmill, some patients may have been able to walk a greater distance in the second test after becoming more familiar with walking on the treadmill relative to the first test. Therefore, we divided the patients into two groups that differed in RIPC administration and a control group.

In this study, a significant increase in the ICD was observed in the second treadmill test for Group A and Group C, and this increase was greater in Group A compared to Group C. All of the groups showed a statistically significant increase in the second treadmill test for the TWD regardless of RIPC treatment. These findings suggested that two factors contributed to an increase in walking distance: RIPC and an increase in patient familiarity with treadmill use. Thus, Group A averaged a significantly higher ICD in the second week when compared to the first week. However, in Group B, the factors responsible for increasing the distance walked (RIPC and treadmill familiarization) appeared to antagonize the effect of each other because of the timing of the treadmill test. If RIPC had no beneficial effect on treadmill performance, then the distance walked in the second test should increase regardless of whether RIPC was administered prior to the first test or the second test; however, this was not the case in our study.

The fact that the TWD did not change upon RIPC treatment is most likely caused by ischemic conditioning, which is expected in claudication patients, as ischemia is the cause of the symptoms of claudication. However, as RIPC activates several signaling pathways, we believe that pathways that are not activated or that are partially activated may become fully activated after RIPC, such as the opioid pathway. We suspect that the activation of other signaling pathways by RIPC could explain why the ICD increased, as opioids may increase tolerance to pain.

Future studies should attempt to identify the biochemical agents responsible for the benefits of RIPC in claudication patients, which could allow for the exogenous administration of these factors to claudication patients bringing relief of symptoms. However, prior to the developing therapeutics for claudication patients, evidence confirming the benefits of RIPC in these individuals is necessary, which was the main objective of our study.

Because RIPC did not change the TWD, RIPC did not appear to be useful for claudication treatment, and conventional treatments involving exercise training (walking and/or exercise with load), risk factor control, smoking cessation and drug therapy with aspirin and simvastatin remain the best therapeutic option. However, as patients with claudication are constantly exposed to ischemic conditioning in the lower limbs and because the lower limbs account for a large proportion of the skeletal muscle, claudication patients are an ideal model to research signaling pathways involved with the RIPC effect as well as the triggers of RIPC. RIPC research can lead to the development of therapeutics that could increase cellular resistance to ischemia in patients subjected to acute ischemia, such as trauma patients or major surgery patients.

Additional studies are needed to clarify the effects of RIPC and the mechanism of action through which tissues

that are not directly subjected to ischemia benefit upon subsequent ischemic insults.

RIPC increases the initial claudication distance in patients with intermittent claudication. However, RIC does not affect the total walking distance of claudication patients.

■ ACKNOWLEDGMENTS

Fundação de Amparo à Pesquisa do Estado de São Paulo (Fapesp); grant numbers: 2008/03203-1.

■ AUTHOR CONTRIBUTIONS

Saes GF and Zerati AE were responsible for the study concept and design, patient recruitment, data collection and manuscript writing. Wolosker N was responsible for the study concept and design, patient recruitment and writing of the manuscript. Ragazzo L was responsible for patient recruitment, data collection and final approval. Rosoky RM was responsible for the study concept and design, and manuscript writing. Ritti-Dias RM, Cucato GG and Chehuen M were responsible for cardiovascular screening and final approval. Farah B was responsible for statistical expertise and final approval. Puech-Leão P provided medical support during the study and approved the final version of the manuscript.

■ REFERENCES

- Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation*. 1986;74(5):1124-36, <http://dx.doi.org/10.1161/01.CIR.74.5.1124>.
- Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. *Circulation*. 1993;87(3):893-9, <http://dx.doi.org/10.1161/01.CIR.87.3.893>.
- Przyklenk K. Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum. *Drugs Aging*. 2011;28(5):331-43, <http://dx.doi.org/10.2165/11587190-000000000-00000>.
- Przyklenk K, Darling CE, Dickson EW, Whittaker P. Cardioprotection 'outside the box'--the evolving paradigm of remote preconditioning. *Basic Res Cardiol*. 2003;98(3):149-57.
- Przyklenk K, Frelinger AL 3rd, Linden MD, Whittaker P, Li Y, Barnard MR, Adams J, Morgan M, Al-Shamma H, Michelson AD. Targeted inhibition of the serotonin 5HT_{2A} receptor improves coronary patency in an in vivo model of recurrent thrombosis. *J Thromb Haemost*. 2010;8(2):331-40, <http://dx.doi.org/10.1111/j.1538-7836.2009.03693.x>.
- Przyklenk K, Heusch G. Late preconditioning against myocardial stunning. Does aspirin close the "second window" of endogenous cardioprotection? *J Am Coll Cardiol*. 2003;41(7):1195-7, [http://dx.doi.org/10.1016/S0735-1097\(03\)00087-1](http://dx.doi.org/10.1016/S0735-1097(03)00087-1).
- Przyklenk K, Li G, Simkhovich BZ, Kloner RA. Mechanisms of myocardial ischemic preconditioning are age related: PKC-epsilon does not play a requisite role in old rabbits. *J Appl Physiol*. 2003;95(6):2563-9.
- Przyklenk K, Li G, Whittaker P. No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. *J Am Coll Cardiol*. 2001;38(6):1741-7, [http://dx.doi.org/10.1016/S0735-1097\(01\)01603-5](http://dx.doi.org/10.1016/S0735-1097(01)01603-5).
- Przyklenk K, Maynard M, Darling CE, Whittaker P. Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of inositol trisphosphate receptors and gap junctions in triggering protection. *J Pharmacol Exp Ther*. 2005;314(3):1386-92, <http://dx.doi.org/10.1124/jpet.105.087742>.
- Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are refractory to infarct size reduction with post-conditioning. *J Am Coll Cardiol*. 2008;51(14):1393-8, <http://dx.doi.org/10.1016/j.jacc.2007.11.070>.
- Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. *Antioxid Redox Signal*. 2011;14(5):781-90, <http://dx.doi.org/10.1089/ars.2010.3343>.
- Przyklenk K, Maynard M, Whittaker P. First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning. *Am J Physiol Heart Circ Physiol*. 2006;291(4):H2008-12, <http://dx.doi.org/10.1152/ajpheart.00313.2006>.
- Przyklenk K, Maynard M, Whittaker P. Reduction of infarct size with D-myo-inositol trisphosphate: role of PI3-kinase and mitochondrial K(ATP) channels. *Am J Physiol Heart Circ Physiol*. 2006;290(2):H830-6.
- Przyklenk K, Undyala VV, Wider J, Sala-Mercado JA, Gottlieb RA, Mentzer RM Jr. Acute induction of autophagy as a novel strategy for cardioprotection: getting to the heart of the matter. *Autophagy*. 2011;7(4):432-3, <http://dx.doi.org/10.4161/auto.7.4.14395>.



15. Przyklenk K, Whittaker P. In vitro platelet responsiveness to adenosine-mediated "preconditioning" is age-dependent. *J Thromb Thrombolysis*. 2005;19(1):5-10.
16. Przyklenk K, Whittaker P. Cardioprotection with adenosine: 'a riddle wrapped in a mystery'. *Br J Pharmacol*. 2005;145(6):699-700.
17. Przyklenk K, Whittaker P. Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals. *Lasers Med Sci*. 2007;22(1):42-5, <http://dx.doi.org/10.1007/s10103-006-0410-1>.
18. Przyklenk K, Whittaker P. Cardioprotection via adaptation to hypoxia: expanding the timeline and targets? *Basic Res Cardiol*. 2011;106(3):325-8, <http://dx.doi.org/10.1007/s00395-011-0169-9>.
19. Nakano A, Heusch G, Cohen MV, Downey JM. Preconditioning one myocardial region does not necessarily precondition the whole rabbit heart. *Basic Res Cardiol*. 2002;97(1):35-9, <http://dx.doi.org/10.1007/s395-002-8385-3>.
20. McClanahan TB, Nao BS, Wolke LJ, Martin BJ, Mezt TE. Brief renal occlusion and reperfusion reduces myocardial infarct size in rabbits. *FASEB J*. 1993;7:A18.
21. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. *Circulation*. 1996;94(9):2193-200, <http://dx.doi.org/10.1161/01.CIR.94.9.2193>.
22. Kharbada RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschitzky JA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. *Circulation*. 2002;106(23):2881-3, <http://dx.doi.org/10.1161/01.CIR.0000043806.51912.9B>.
23. Ateş E, Genç E, Erkasap N, Erkasap S, Akman S, Firat P, et al. Renal protection by brief liver ischemia in rats. *Transplantation*. 2002;74(9):1247-51, <http://dx.doi.org/10.1097/00007890-200211150-00009>.
24. Mallick IH, Yang W, Winslet MC, Seifalian AM. Ischaemic preconditioning improves microvascular perfusion and oxygenation following reperfusion injury of the intestine. *Br J Surg*. 2005;92(9):1169-76.
25. Gurusamy KS, Gonzalez HD, Davidson BR. Current protective strategies in liver surgery. *World J Gastroenterol*. 2010;16(48):6098-6103.
26. Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury—a review. *J Surg Res*. 2008;150(2):304-30, <http://dx.doi.org/10.1016/j.jss.2007.12.747>.
27. Stewart KJ, Hiatt WR, Regensteiner JC, Hirsch AT. Exercise training for claudication. *N Engl J Med*. 2002;347(24):1941-51.
28. Wolosker N, Nakano L, Rosoky RA, Puech-Leao P. Evaluation of walking capacity over time in 500 patients with intermittent claudication who underwent clinical treatment. *Arch Intern Med*. 2003;163(19):2296-300, <http://dx.doi.org/10.1001/archinte.163.19.2296>.
29. Dickson EW, Reinhardt CP, Renzi FP, Becker RC, Porcaro WA, Heard SO. Ischemic preconditioning may be transferable via whole blood transfusion: preliminary evidence. *J Thromb Thrombolysis*. 1999; 8(2):123-9, <http://dx.doi.org/10.1023/A:1008911101951>.
30. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. *Circulation*. 1997;96(5):1641-6, <http://dx.doi.org/10.1161/01.CIR.96.5.1641>.
31. Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, Inubushi T, et al. Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits: effects of "remote preconditioning". *J Am Coll Cardiol*. 1999;33(2):556-64, [http://dx.doi.org/10.1016/S0735-1097\(98\)00559-2](http://dx.doi.org/10.1016/S0735-1097(98)00559-2).
32. Patel HH, Moore J, Hsu AK, Gross GJ. Cardioprotection at a distance: mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. *J Mol Cell Cardiol*. 2002;34(10):1317-23, <http://dx.doi.org/10.1006/jmcc.2002.2072>.
33. Harkin DW, Barros D'Sa AA, McCallion K, Hoper M, Campbell FC. Ischemic preconditioning before lower limb ischemia-reperfusion protects against acute lung injury. *J Vasc Surg*. 2002;35(6):1264-73, <http://dx.doi.org/10.1067/mva.2002.121981>.
34. Lai IR, Chang KJ, Chen CF, Tsai HW. Transient limb ischemia induces remote preconditioning in liver among rats: the protective role of heme oxygenase-1. *Transplantation*. 2006;81(9):1311-7, <http://dx.doi.org/10.1097/01.tp.0000203555.14546.63>.
35. Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M, et al. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. *Am J Physiol Heart Circ Physiol*. 2003;285(4):H1435-43.
36. Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield JE, MacAllister RJ. Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. *J Am Coll Cardiol*. 2005;46(3):450-6, <http://dx.doi.org/10.1016/j.jacc.2005.04.044>.
37. Loukogeorgakis SP, Williams R, Panagiotidou AT, Kolvekar SK, Donald A, Cole TJ, et al. Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. *Circulation*. 2007;116(12):1386-95, <http://dx.doi.org/10.1161/CIRCULATIONAHA.106.653782>.
38. Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J, et al. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial. *Heart*. 2009;95(19):1567-71, <http://dx.doi.org/10.1136/hrt.2008.155770>.
39. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, et al. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. *Basic Res Cardiol*. 2010;105(5):657-64, <http://dx.doi.org/10.1007/s00395-010-0104-5>.
40. Gurusamy KS, Kumar Y, Pamecha V, Sharma D, Davidson BR. Ischaemic pre-conditioning for elective liver resections performed under vascular occlusion. *Cochrane Database Syst Rev*. 2009;(1):CD007629.
41. Eng J. Sample size estimation: how many individuals should be studied? *Radiology*. 2003;227(2):309-13, <http://dx.doi.org/10.1148/radiol.2272012051>.